Shortness of breath: Is it chronic obstructive pulmonary disease?

Australian Family Physician

Volumn 34, Issue 7, 2005, Pages 541-544

  McDonald, Christine F ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID;

ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION; DRUG COMBINATION; DYSPNEA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; OXYGEN THERAPY; REVIEW; SMOKING CESSATION; SPIROMETRY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; DYSPNEA; HUMANS; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; SMOKING CESSATION; SPIROMETRY;

EID: 25144460645     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76.
2. McKenzie DK, Frith PA, Burdon JGW, Town IG. The COPDX plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Med J Aust 2003;178:(Suppl 6)S7-39.
3. Celli BR, Cote CG, Marin JM, et al. The BMI, airflow obstruction, dyspnea and exercise capacity index in COPD. New Engl J Med 2004;350:1005-12.
4. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop smoking rate. Chest 2003;123:1916-23.
5. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
6. Nannini L, Cates CJ, Lasserson TJ, et al. Cochrane Database Syst Rev 2004;(3):CD003794.
7. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271-4.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. Availabe at: www.gold.com.
9. Eaton T, Garrett JE, Young P, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled trial. Eur Respir J 2002;20:306-12.
10. McDonald CF, Crockett A, Young I. Adult domiciliary oxygen therapy. Position Statement of the Thoracic Society of Australia and New Zealand. Med J Aust 2005; in press.
11. Rea H, McAuley S, Stewart A, et al. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern Med J 2004;34:608-14.
12. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.